Effects of intravenous nicardipine followed by oral labetalol in combination with nifedipine controlled-release tablet on severe peripartum hypertension.

Ginekologia polska Pub Date : 2024-01-01 Epub Date: 2024-02-09 DOI:10.5603/gpl.97752
Lan Lan, Yunsheng Yan, Haifeng Qi, Jiali Qin, Lan Li, Shengwen Gan, Ruoxuan Zhang, Yaozong Zhang
{"title":"Effects of intravenous nicardipine followed by oral labetalol in combination with nifedipine controlled-release tablet on severe peripartum hypertension.","authors":"Lan Lan, Yunsheng Yan, Haifeng Qi, Jiali Qin, Lan Li, Shengwen Gan, Ruoxuan Zhang, Yaozong Zhang","doi":"10.5603/gpl.97752","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the effects of intravenous nicardipine as initial therapy and oral labetalol combined with nifedipine controlled-release tablet as subsequent treatment of severe peripartum hypertension.</p><p><strong>Material and methods: </strong>Intravenous nicardipine was delivered as the initial treatment, after the target blood pressure (BP) had been achieved, oral labetalol was used to maintain the target BP. If oral labetalol failed to maintain the target BP, oral labetalol combined with nifedipine controlled-release tablet was used.</p><p><strong>Results: </strong>A total number of 131 patients were enrolled. The target BP (BP < 140/90 mmHg) was achieved in all patients within 60 minutes by intravenous nicardipine. After receiving labetalol orally, the target BP was maintained in nine patients. However, in 104 patients, we had to combine oral labetalol and nifedipine controlled-release tablet due to re-elevation of their systolic BP to 140-159 mmHg. In 18 patients, we restarted intravenous nicardipine because their systolic BP re-elevated above 160 mm Hg. Among the 104 patients who received oral labetalol and nifedipine controlled-release tablet, the target BP was achieved and maintained in 96 patients, and eight patients had to restart nicardipine. Of the total number of 26 patients in whom intravenous nicardipine was resumed, the target BP was successfully maintained in 22 patients with oral labetalol combined with nifedipine controlled-release tablet.</p><p><strong>Conclusions: </strong>Intravenous nicardipine rapidly and safely lowered severe peripartum hypertension. As subsequent therapy, oral labetalol combined with nifedipine controlled-release tablet protocol may be applied to effectively maintain a target BP.</p>","PeriodicalId":94021,"journal":{"name":"Ginekologia polska","volume":" ","pages":"536-543"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ginekologia polska","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/gpl.97752","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To investigate the effects of intravenous nicardipine as initial therapy and oral labetalol combined with nifedipine controlled-release tablet as subsequent treatment of severe peripartum hypertension.

Material and methods: Intravenous nicardipine was delivered as the initial treatment, after the target blood pressure (BP) had been achieved, oral labetalol was used to maintain the target BP. If oral labetalol failed to maintain the target BP, oral labetalol combined with nifedipine controlled-release tablet was used.

Results: A total number of 131 patients were enrolled. The target BP (BP < 140/90 mmHg) was achieved in all patients within 60 minutes by intravenous nicardipine. After receiving labetalol orally, the target BP was maintained in nine patients. However, in 104 patients, we had to combine oral labetalol and nifedipine controlled-release tablet due to re-elevation of their systolic BP to 140-159 mmHg. In 18 patients, we restarted intravenous nicardipine because their systolic BP re-elevated above 160 mm Hg. Among the 104 patients who received oral labetalol and nifedipine controlled-release tablet, the target BP was achieved and maintained in 96 patients, and eight patients had to restart nicardipine. Of the total number of 26 patients in whom intravenous nicardipine was resumed, the target BP was successfully maintained in 22 patients with oral labetalol combined with nifedipine controlled-release tablet.

Conclusions: Intravenous nicardipine rapidly and safely lowered severe peripartum hypertension. As subsequent therapy, oral labetalol combined with nifedipine controlled-release tablet protocol may be applied to effectively maintain a target BP.

静脉注射尼卡地平后口服拉贝洛尔联合硝苯地平控释片对重度围产期高血压的影响。
目的研究静脉注射尼卡地平作为初始治疗,口服拉贝洛尔联合硝苯地平控释片作为重度围产期高血压后续治疗的效果:材料:静脉注射尼卡地平作为初始治疗,在达到目标血压(BP)后,使用口服拉贝洛尔维持目标血压。如果口服拉贝洛尔不能维持目标血压,则使用口服拉贝洛尔联合硝苯地平控释片:共有 131 名患者入选。所有患者均在 60 分钟内通过静脉注射尼卡地平达到目标血压(血压 < 140/90 mmHg)。口服拉贝洛尔后,9 名患者的目标血压得以维持。然而,在 104 名患者中,由于收缩压再次升高至 140-159 mmHg,我们不得不将口服拉贝洛尔和硝苯地平控释片合二为一。在 18 名患者中,由于收缩压再次升高至 160 毫米汞柱以上,我们重新开始静脉注射尼卡地平。在口服拉贝洛尔和硝苯地平控释片的 104 名患者中,96 名患者达到并维持了目标血压,8 名患者不得不重新开始服用尼卡地平。在重新开始静脉注射尼卡地平的 26 名患者中,有 22 名患者通过口服拉贝洛尔和硝苯地平控释片成功维持了目标血压:结论:静脉注射尼卡地平能快速、安全地降低严重的围产期高血压。结论:静脉注射尼卡地平能快速、安全地降低严重的围产期高血压,作为后续治疗,口服拉贝洛尔联合硝苯地平控释片可有效维持目标血压。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信